Riskpilot← Back to searchSign inGet full accessNORDIC PHARMA INC AS
ASActiveOrg 989166514Ropnesvegen 71, 9107 KvaløyaManufacture of oils and fats · NACE 1041Est. 200654 employeeswww.noromega.no
Revenue 2024
NOK 288,8M
+9% vs 2023
EBITDA margin
28.8%
+13% vs 2023
Equity ratio
65.6%
Financial strength
Net profit 2024
NOK 41,7M
+58% vs 2023
| Revenue | NOK 288,8M | +9% |
| EBITDA | NOK 83,1M | +13% |
| Net profit | NOK 41,7M | +58% |
| Total assets | NOK 503,6M | +9% |
| Equity | NOK 330,2M | +14% |
| Employees | 54 | — |
Legal name
NORDIC PHARMA INC AS
Org number
989166514
Legal form
Aksjeselskap
NACE code
1041 · Manufacture of oils and fats
Founded
14. januar 2006
Share capital
NOK 27 908 300
Employees
54 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Investere i- og utvikle næringsvirksomhet innen kosttilskudd, funksjonell mat og bioteknologi og marine ressurser, herunder delta i andre virksomheter gjennom aksjeeie eller på annen måte, og hva hermed står i forbindelse.
Address
Ropnesvegen 71, 9107 Kvaløya
Phone
+4777668660
Email
post@nordicpharmainc.com
Website
www.noromega.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 202 357 | 176 563 | 199 015 | 264 923 | 288 844 |
| Staff expenses | −22 673 | −19 834 | −29 866 | −28 515 | −30 219 |
| EBITDA | 80 585 | 71 859 | 72 114 | 73 442 | 83 087 |
| Depreciation & amort. | −17 898 | −19 230 | −22 135 | −23 314 | −25 857 |
| EBIT | 62 687 | 52 629 | 49 979 | 50 128 | 57 230 |
| Net financials | 1 807 | −1 821 | −7 654 | −16 254 | −3 855 |
| Profit before tax | 64 494 | 50 808 | 42 325 | 33 874 | 53 375 |
| Tax | 14 189 | 11 184 | 9 312 | 7 456 | 11 671 |
| Net profit | 50 305 | 39 624 | 33 013 | 26 418 | 41 704 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 383 824 | 419 789 | 455 527 | 460 408 | 503 593 |
| Equity | 189 413 | 229 038 | 262 051 | 288 469 | 330 173 |
| Long-term debt | 146 720 | 134 639 | 165 128 | 146 858 | 135 293 |
| Short-term debt | 47 690 | 56 113 | 28 348 | 25 081 | 38 128 |
| Total debt | 194 410 | 190 752 | 193 476 | 171 939 | 173 420 |
EBITDA margin
28.8%
This company
15.8%
Market median
+82% vs market
20202024
Equity ratio
65.6%
This company
38.2%
Market median
+72% vs market
20202024
Return on equity
12.6%
This company
18.4%
Market median
+32% vs market
20202024
Net profit margin
14.4%
This company
8.1%
Market median
+78% vs market
20202024
Asset turnover
0.57×
This company
1.12×
Market median
-49% vs market
20202024
Debt / equity
0.53×
This company
0.62×
Market median
+15% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GB Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Chairman | 2021 | |
| Former (1) | ||
| Board of Directors | 2021 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 71.38% | 71.38% | 2022 | |
A-O Irrevocable Trust | Company | 35.69% | 35.69% | 2023 |
I-O Irrevocable Trust | Company | 35.69% | 35.69% | 2023 |
Ao Irrevocable Trust | Company | 35.69% | 35.69% | 2024 |
Io Irrevocable Trust | Company | 35.69% | 35.69% | 2024 |
| Individual | 28.62% | 28.62% | 2022 | |
A-O Irrevocable Trust | Company | 14.31% | 14.31% | 2023 |
Ao Irrevocable Trust | Company | 14.31% | 14.31% | 2024 |
I-O Irrevocable Trust | Company | 14.31% | 14.31% | 2023 |
Io Irrevocable Trust | Company | 14.31% | 14.31% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NORDIC PHARMA INC AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gorm Breimo | Chief Executive Officer | 0 companies |
| Joar Arild Opheim | Board of Directors | 0 companies |
| Ingrid Asta Opheim | Board of Directors | 0 companies |
| Astrid Opheim | Chairman | 0 companies |